Biomodels Pre-Clinical CRO for Mucosal Injury (Mucositis), Cancer and Inflammation Studies
Biomodels, founded in 1997, provides pre-clinical efficacy studies for drug development. We work closely with our clients to provide customized programs to demonstrate efficacy data (non-GLP) for regulatory submissions. Our expertise in cancer supportive care is based on the life-long work of Dr Stephen T Sonis.
We are world leaders in pre-clinical models relating to the side effects of chemotherapy and radiation treatments. Biomodels provides many additional models in the areas of oncology and inflammatory and cardiovascular diseases. We provide models that are clinically relevant and predictive. Our studies are customized to the specific needs of our clients; the studies are timely and are performed to the highest standards by our skilled scientists and technicians.
Oral mucositis studies
Cancer supportive care is the treatment and prevention of the side effects of cancer chemotherapy and radiation therapy; Biomodels is best known for our studies of oral mucositis. We have also developed study protocols in the areas of proctitis, osteonecrosis, fatigue, dermatitis and neurological toxicity.
Human tumor xenograft models
We offer a wide range of conventional human tumor xenograft models for a broad spectrum of cancer indications as well as a number of syngenic and orthotopic models in indications where these models are particularly relevant. In addition to the in vivo models for cancer, we offer a wide range of in vitro testing services for preliminary evaluation of anti-neoplastics.
Recognizing the need for early target screening, Biomodels also offers a target evaluation service which facilitates the screening of a range of different tumor types as both cell cultures and solid tumors for the expression of genes and proteins of interest.
Models of antigen-induced autoimmune disease
Biomodels’ expertise in inflammatory disease stems from our interest in oral mucositis, and other complications of cancer therapy that involve the immune system. We offer models of antigen-induced autoimmune disease such as collagen-induced arthritis (a model and myelin peptide-induced experimental allergic encephalomyelitis [EAE; a model of multiple sclerosis]).
Models of IBD with endoscopy
In addition, we offer chemically induced models of inflammatory bowel disease (IBD) / ulcerative colitis utilizing video endoscopy. Validated models include induction by DSS, TNBS and Oxalazone. We also offer models of surgically induced osteoarthritis and nephritis.
Evaluation of arterial and venous thrombosis
In the cardiovascular disease area Biomodels has developed novel models for the evaluation of arterial and venous thrombosis, which evaluate blood flow in a major vessel directly using video microscopy and Doppler flow measurement. In addition, Biomodels offers models for the assessment of clotting time and blood pressure, by either tail cuff or direct measurement. Biomodels also offers models of atherosclerosis and stroke using either surgical modifications or genetic models.
Customized pre-clinical models
Over the past 12 years we have developed over 100 customized models for individual clients. Often this is a matter of transferring and validating studies from academic publications to a commercial setting. We have successfully carried out custom work in the areas of obesity, diabetes, radioprotection, acute toxicology (LD50 and MTD), asthma and fibrosis.
Products and Services
Erleada (apalutamide) for the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer
Kymriah (tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukaemia
Truxima (rituximab) for the Treatment of Cancer
Imfinzi (durvalumab) for the Treatment of Metastatic Urothelial Carcinoma (mUC)
Zinplava (bezlotoxumab) for the Treatment of Clostridium Difficile Infection
Cabometyx (cabozantinib) for Treatment of Patients with Advanced Renal Cell Carcinoma
Avaxia Biologics to Collaborate with Biomodels on Antibody Therapeutic for Inflammatory Bowel Disease
Avaxia Biologics, a biotechnology company developing oral antibodies for diseases of the GI tract, has announced that it has been awarded a Phase I Small Business Innovation Research grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of HRead more
Biomodels’ Oral Mucositis Expertise Speeds Up FDA Approval for ActoGeniX’s Phase 1b Trial of AGO13 in Cancer Patients
Pre-clinical research organisation Biomodels has announced that it has successfully collaborated with ActoGeniX, a development stage biopharmaceutical company, in obtaining FDA approval for an Investigational New Drug (IND) application for AGO13, a novel therapeutic product for the treatment of oRead more
Scientists at Biomodels have successfully developed the first model that accurately duplicates human cancer treatment-related fatigue (CTRF). The new model shows that, as in human cancer patients, fatigue is independent of anaemia or weight loss and persists long after cancer treatments end.Read more
Medical researchers have reported findings demonstrating that injecting the protein lubricin into knee joints can dramatically reduce cartilage degeneration. The discovery by scientists at Biomodels, a preclinical drug research organisation, and Lubris, a Massachusetts-based start-up coRead more